Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a68Ga- And18F-labeled hapten peptide in mice with human tumor xenografts

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 1019-1027

  Schoffelen, Rafke ^a   Sharkey, Robert M ^b   Goldenberg, David M ^b   Franssen, Gerben ^a   McBride, William J ^c   Rossi, Edmund A ^d   Chang, Chien Hsing ^c,d   Laverman, Peter ^a   Disselhorst, Jonathan A ^a   Eek, Annemarie ^a   Van Der Graaf, Winette T A ^a   Oyen, Wim J G ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Garden State Cancer Center   (Canada)

^c IBC Pharmaceuticals Inc   (United States)

^d IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7 TRIAZACYCLONONANE N,N,N'' TRIACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; HAPTEN; HISTAMINE SUCCINYLGLYCINE; IMP 288; IMP 449; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TF2; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; CARCINOEMBRYONIC ANTIGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HAPTENS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950816505     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0862     Document Type: Article

References (31)

1. Jain RK. Physiological barriers to delivery of monoclonal antibodles and other macromolecules in tumors. Cancer Res 1990;50:814-9s.
2. 2. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 2006;11:7109-7121 a. (Pubitemid 41428712)
3. Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature 1985; 316:265-268
4. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radloimmunotherapy of cancer: progress step by step. J Nucl Med 2003;44:400-411
5. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1:553-563
6. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification In molecular Imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-1255
7. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and In vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-1366
8. Karacay H, McBride WJ, Griffiths GL, et al. Experimental pretargeting studies of cancer with a humanized antl-CEA x murine anti-[ln-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide. Bioconjug Chem 2000;11:842-854
9. 68Ga-radlolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med 2004;45: 30-39
10. 124l-labeled hapten-peptide. J Nucl Med 2006;47:1678-1688
11. 11. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354-363 (Pubitemid 36152493)
12. Sharkey RM, Karacay H, Vallabhajosula S, et al. Metastatic human colonic carcinoma: molecular Imaging with pretargeted SPECT and PET in a mouse model. Radiology 2008;246:497-507.
13. 18F radlolabellng for PET. J Nucl Med 2009;50:991-998
14. 14. Morel A, Darmon M, Delaage M. Recognition of imidazole and histamlneaderivatlves by monoclonal antibodies. Mol Immunol 1990;27:995-1000. (Pubitemid 20341203)
15. 15. Sharkey RM, Goldenberg DM, Goldenberg H, et al. Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans. Cancer Res 1990;50:2823-2831 (Pubitemid 20150228)
16. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008;49:158-163
17. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006;103:6841-6846
18. 18. Llndmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89. (Pubitemid 14091996)
19. Fraker PJ, Speck JC, Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6adlphrenylglycoluril. Biochem Blophys Res Commun 1978;80:849-857
20. 20. Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 1990;50:5531-6. 21. Van der Laken CJ, Boerman OC, Oyen WJ, et al. In vivo expression of interleukin-1 receptors during various experimentally induced inflammatory conditions. J Infect Dis 1998;177:1398-1401 (Pubitemid 20303015)
21. Visser EP, Disselhorst JA, Brom M, et al. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med 2009;50:139-147
22. Van de Wiele C, Revets H, Mertens N. Radioimmunoimaging. Advances and prospects. QJ Nucl Med Mol Imaging 2004;48:317-325
23. Goldenberg DM. Perspectives on oncologic Imaging with radiolabeled antibodies. Cancer 1997;80:2431-2435
24. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J 2008;14:191-197
25. 18F-labeled T84.66 anticarclnoembryonic antigen dlabody. J Nucl Med 2007;48:304-310
26. 27. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody lgG and fragments In nude mice bearing human colonic tumor xenografts. Cancer Res 1990;50:2330-2336 (Pubitemid 20134490)
27. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-1189
28. 29. Ghetie V, Ward ES. FcRn: the MHC class-l-related receptor that Is more than an IgG transporter. Immunol Today 1997;18:592-598 (Pubitemid 28012280)
29. Chinn PC, Morena RA, Santoro DA, et al. Pharmacokinetics and tumor localization of (111)ln-labeled HuCC49AC(H)2 In BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biother Radlopharm 2006;21:106-116
30. Slavin-Chiorlni DC, Kashmiri SV, Lee HS, et al. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 1997;12:305-316
31. 32. Sharkey RM, Karacay H, Richel H, et al. Optimizing bispecific antibody pretargeting for use in radiolmmunotherapy. Clin Cancer Res 2003;9:3897-913S. (Pubitemid 36152493)